RxDoctor Payments Data

Juliet Wong, NP

Adult Health · Rochester, NYNPI 1639816325

Payments from drug & device makers

$1,483in general payments, 2019–2025

Across 34 payments — averaging $43.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$548
  • Amgen$209
  • Novo Nordisk$173
  • Tandem Diabetes Care, Inc.$135
  • Cequr Corporation$134
  • Dexcom, Inc.$115
  • plus $168 from 5 others

What the payments were for

  • Food & beverage$1,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,483 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$22,239
Medicare patients
133
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide420$479,416
JardianceEmpagliflozin268$280,694
TrulicityDulaglutide158$212,177
MounjaroTirzepatide126$148,032
RybelsusSemaglutide63$73,866
Humulin R U-500 KwikpenInsulin Regular, Human48$70,231
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/754$63,236
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog145$62,071
Insulin Lispro Kwikpen U-100Insulin Lispro252$56,136
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$46,323
FarxigaDapagliflozin Propanediol64$45,125
Lantus SolostarInsulin Glargine,hum.Rec.Anlog413$44,519
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog66$43,683
JanuviaSitagliptin Phosphate36$31,112
Humalog Kwikpen U-100Insulin Lispro66$22,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$173$560,888504 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$548$372,160350 claims
Cequr CorporationCequr Simplicity$134$4,87811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.

Other adult health in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →